What a Year on Omnipod 5 Reveals About Blood Sugar Control and Eye Health

Most research on insulin pumps happens in controlled settings. This study took a different approach: researchers reviewed actual medical records and glucose data from 100 adults with Type 1 diabetes who had started using the Omnipod 5 hybrid closed-loop system. The group was fairly typical—median age 28, about 63% women, and most had lived with Type 1 diabetes for roughly 16 years. Over half came from multiple daily injections, switching to pump therapy for the first time.

By looking at real-world outcomes over a full year, the researchers hoped to understand not just whether blood sugar improved, but whether those improvements lasted and what happened to other health markers like eye disease and kidney function.

At the start, participants had a median HbA1c of 68 mmol/mol—above the typical target range. Within 3 months of beginning Omnipod 5, HbA1c dropped notably. By month 12, the average HbA1c had fallen to 58.8 mmol/mol, representing meaningful improvement in long-term blood sugar control.

What made this especially important was the durability of the change. Blood sugar control didn't just spike and drop; it remained stable throughout the year of follow-up. This suggests that Omnipod 5 provided consistent, sustained benefit for this group.

Beyond blood sugar numbers, researchers looked at diabetic retinopathy—damage to blood vessels in the eye that can affect vision. They found something unexpected: retinopathy appeared to progress more in people whose starting blood sugar levels were already above the target range.

This is an important observation but not yet a proven cause-and-effect relationship. The researchers themselves emphasize this is 'preliminary data' that 'generates the hypothesis' for future study. It suggests that when people start pump therapy, their baseline blood sugar level may influence risk of eye disease progression—but larger, more carefully designed studies are needed to confirm this pattern.

This study had strengths—real-world data, 12-month follow-up, and a focus on health markers beyond HbA1c—but also limitations. It was a single center looking backward at medical records rather than a prospective trial randomly assigning people to treatment. Kidney function and other cardiometabolic markers were assessed, but the researchers called for more rigorous future studies.

The takeaway for people with Type 1 diabetes considering or using closed-loop systems like Omnipod 5: real-world data supports sustained benefits for blood sugar control. But broader questions about long-term effects on eye health, heart health, and other complications remain an active area of research.

Source: Diabetes, obesity & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.